InflaRx N.V. (NASDAQ:IFRX) Given Average Rating of “Moderate Buy” by Analysts

InflaRx N.V. (NASDAQ:IFRX) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $6.1667.

A number of research firms have commented on IFRX. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. Finally, Guggenheim decreased their target price on InflaRx from $22.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 20th.

Institutional Investors Weigh In On InflaRx

Hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC raised its position in shares of InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after purchasing an additional 135,826 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in InflaRx in the 2nd quarter valued at $262,000. Boothbay Fund Management LLC increased its stake in InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after purchasing an additional 17,056 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in InflaRx during the 3rd quarter valued at $214,000. Finally, Quadrature Capital Ltd acquired a new position in InflaRx during the fourth quarter worth $104,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Performance

InflaRx stock opened at $0.91 on Friday. The stock has a market capitalization of $65.96 million, a price-to-earnings ratio of -1.20 and a beta of 1.49. InflaRx has a 52-week low of $0.71 and a 52-week high of $1.94. The stock’s 50 day moving average price is $0.91 and its two-hundred day moving average price is $1.11.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Friday, March 20th. The company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of ($0.04) million during the quarter, compared to the consensus estimate of $0.03 million. On average, equities research analysts forecast that InflaRx will post -1.04 EPS for the current year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.